ARUP LABORATORIES | aruplab.com
500 Chipeta Way, Salt Lake City, Utah 84108-1221
phone: 801-583-2787, toll free: 800-522-2787
Jonathan R. Genzen, MD, PhD, Chief Medical Officer

PATIENT REPORT

Patient Age/Sex: Unknown

Specimen Collected: 11-Sep-23 08:50

MOG Ab IgG CBA-IFA Screen, CSF |**Received: 11-Sep-23 08:51** **Report/Verified: 11-Sep-23 08:54**

Procedure	Result	Units	Reference Interval
MOG Ab IgG CBA-IFA Scrn,CSF	**Detected** * t1 i1		

MOG Ab IgG CBA-IFA Titer, CSF |**Received: 11-Sep-23 08:51** **Report/Verified: 11-Sep-23 08:54**

Procedure	Result	Units	Reference Interval
MOG Ab IgG CBA-IFA Titer,CSF	**1:80** * i2		[< 1:1]

Interpretive Text

t1: 11-Sep-23 08:50 (MOG Ab IgG CBA-IFA Scrn, CSF)
MOG Antibody, IgG is detected. Titer results to follow.

Test Information

i1: MOG Ab IgG CBA-IFA Scrn, CSF

INTERPRETIVE INFORMATION: MOG Ab IgG CBA-IFA Screen, CSF

Myelin oligodendrocyte glycoprotein (MOG) antibody is found in a subset of patients with neuromyelitis optica spectrum disorders, including optic neuritis and transverse myelitis, brainstem encephalitis, and acute disseminated encephalomyelitis. Persistence of antibody positivity may be associated with a relapsing course; decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of CNS demyelinating disease. Low antibody titers have a lower positive predictive value of disease, and should be carefully interpreted in the context of the patient's clinical history, neurologic exam, imaging, and other laboratory findings. Serum is the preferred specimen type, but in some cases patients with MOG-associated disease may be positive only in CSF; CSF positivity may be associated with more severe clinical outcomes.

This indirect fluorescent antibody assay utilizes full-length MOG transfected cell lines for the detection and semiquantification of MOG IgG antibody.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

i2: MOG Ab IgG CBA-IFA Titer, CSF

INTERPRETIVE DATA: MOG Ab IgG CBA-IFA Titer, CSF

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the U.S. Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

*=Abnormal, #=Corrected, C=Critical, f=Result Footnote, H-High, i-Test Information, L-Low, t-Interpretive Text, @=Performing lab